SCHEMBL14448032

SCHEMBL14448032

CCC(C)CC(C)CC(C)CC(C)COP(=O)(O)OCC[N+](C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FABP3 P05413 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ PLA2G10 O15496 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ AKT1 P31749 2/20 0.35
▸ ESR1 P03372 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ CDC25A P30304 1/20 0.35
▸ AGTR1 P30556 1/20 0.35
▸ ADRA1A P35348 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ PRKD3 O94806 1/20 0.33
▸ PRKCG P05129 1/20 0.33
▸ PRKCB P05771 1/20 0.33
▸ PRKCA P17252 1/20 0.33
▸ PRKCH P24723 1/20 0.33
▸ PRKCI P41743 1/20 0.33
▸ PRKCE Q02156 1/20 0.33
▸ PRKCQ Q04759 1/20 0.33
▸ PRKCZ Q05513 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13480679 0.91 FABP3 (0.48) FABP3SMN1; SMN2PLA2G10LMNAAKT1
SCHEMBL21973787 0.85 FABP3 (0.42) FABP3SMN1; SMN2PLA2G10LMNAAKT1
SCHEMBL21973977 0.84 FABP3 (0.41) FABP3SMN1; SMN2PLA2G10LMNAAKT1
SCHEMBL10013704 0.83 SMN1; SMN2 (0.50) FABP3SMN1; SMN2PLA2G10LMNAAKT1
SCHEMBL5959370 0.79 FABP3 (0.48) FABP3SMN1; SMN2PLA2G10LMNAAKT1
SCHEMBL10013706 0.78 SMN1; SMN2 (0.53) FABP3SMN1; SMN2LMNAAKT1ESR1
SCHEMBL14031370 0.78 SMN1; SMN2 (0.53) FABP3SMN1; SMN2LMNAAKT1ESR1
SCHEMBL25857265 0.77 SMN1; SMN2 (0.46) FABP3SMN1; SMN2LMNAAKT1ESR1
SCHEMBL13299315 0.76 SMN1; SMN2 (0.49) FABP3SMN1; SMN2LMNAAKT1ESR1
SCHEMBL15127116 0.76 SMN1; SMN2 (0.50) FABP3SMN1; SMN2PLA2G10LMNAAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167408-A1 NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF ZENTARIS GMBH (DE) 2007-07-19 — — US disclosed
WO-2007071658-A2 ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF ÆTERNA ZENTARIS GMBH (DE) 2007-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167408-A1 NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF PHOSPHO1, PTDSS1, PTDSS2 FABP3 1765/4885SMN1; SMN2 3176/4885PLA2G10 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback